Olaparib AZD-2281 CAS 763113-22-0 Mama ≥99.0% API Falegaosi
Mamalu Maualuga, Gaosiga Faapisinisi
Olaparib ma Fesootaʻiga Faʻatasi:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Igoa Vailaau | Olaparib |
| Synonyms | AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-tasi;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| Numera CAS | 763113-22-0 |
| CAT Numera | RF-API103 |
| Tulaga Fa'asoa | I Fa'atauga, Oloa Fua e O'o i le selau Kilograms |
| Fuafua mole | C24H23FN4O3 |
| Molecular Weight | 434.46 |
| Solubility | Solu i le DMSO |
| Fa'ailoga | Ruifu Chemical |
| Aitema | Fa'amatalaga |
| Fa'aaliga | Pa'epa'e i le Pa'epa'e Pa'epa'e |
| Fa'ailoaina e le 1H NMR | Tausi ma le fausaga |
| LC-MS | Tausi ma le fausaga |
| Mama / Suʻesuʻega Metotia | ≥99.0% (e LC-MS) |
| Susū (KF) | ≤0.50% |
| Le mama nofofua | ≤0.50% |
| Aofa'i Fa'aleaga | ≤1.0% |
| Metala mamafa (pei o le Pb) | ≤20ppm |
| Tulaga Su'ega | Pisinisi Tulaga |
| Fa'aoga | API;PARP Inhibitor |
afifi: Fagu, Ato pepa alumini, Pusa Pusa, 25kg / Paʻu, poʻo e tusa ai ma manaʻoga o tagata faʻatau.
Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu.
Olaparib (CAS: 763113-22-0), o se PARP-inhibitor sili ona malosi ma filifilia.Ia Tesema 19, 2014, na faamaonia ai e le FDA le tala fou e tetee atu ai i le kanesa o Olaparib (Lynparza) mo le monotherapy i tagata mamaʻi o le kanesa ovarian maʻi ua maeʻa ia le itiiti ifo ma le 3 taamilosaga o le chemotherapy poʻo tagata gasegase masalomia BRCA suiga.I le taimi lava e tasi, na faʻamaonia e le FDA le aofaʻi ma le faʻavasegaina o pusa faʻamaonia mo le suʻeina o suiga ile BRCA1 ma BRCA2, BRACAnalysis CDx.Olaparib o le PARP inhibitor muamua lea ua faʻamaonia e le FDA.Ia Fepuari 2, 2015, na faʻamaonia ai foi e le European Union Food and Drug Administration (EMA) Olaparib e ulufale atu i le maketi i atunuu e 28 o Europa e aofia ai Iceland, Liechtenstein ma Nouei.Ae o faʻailoga a le EMA ma le FDA ua faʻamaonia e fai sina eseesega;o le mea muamua e mo le BRCA gene mutation mataupu, faʻapea foʻi ma le tausiga o togafitiga mo tagata mamaʻi o le epithelial ovarian kanesa o loʻo maua muamua vailaʻau chemotherapy o loʻo i ai le platinum ma faʻaalia tali ma e mafai ona toe foʻi mai.
